Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema

Introduction: Chronic bronchitis and emphysema are two COPD phenotypes that can affect pharmacologic treatment decisions. Aims: Tiotropium (T) + olodaterol (O) was established for COPD treatment in two large Phase III trials. This post hoc analysis assessed the effect of T+O on lung function, symptoms and health-related quality of life (QoL) in patients (pts) with investigator-defined bronchitis and/or emphysema. Methods: TONADO ® 1+2 were replicate, randomised, double-blind, parallel-group trials. Pts with GOLD 2–4 COPD were randomised to once-daily T+O 2.5/5 or 5/5 µg, T 2.5 or 5 µg, or O 5 µg via Respimat ® inhaler. 1 End points included forced expiratory volume in 1 second (FEV 1 ) area under the curve from 0–3 hours (AUC 0–3 ) and trough FEV 1 responses, St George9s Respiratory Questionnaire (SGRQ) and Mahler Transition Dyspnoea Index (TDI). We show results for T+O 5/5 µg, T 5 µg and O 5 µg at Week 24. Results: Baseline characteristics were similar between pts with bronchitis (n=2210), emphysema (n=2351) or both (n=1179). Significant improvements in lung function and improvements in SGRQ and TDI were observed with T+O in all groups (Table). Conclusions: In moderate to severe COPD, T+O improves lung function, symptoms and QoL in all pts. Improvements in emphysema pts were slightly superior than in chronic bronchitis pts. Reference: 1. Buhl R et al. Eur Respir J 2015;45:969–79. Funding: Boehringer Ingelheim.